Canakinumab for the treatment of TNF-receptor associated periodic syndrome (TRAPS)

ABSTRACTIntroduction: Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) is a rare autoinflammatory disease. Although exact pathogenesis is still not fully understood, it is clear that IL-1β production plays a pivotal role in determining the clinical features and represent a good target for treatment.Areas covered: This review will briefly describe the characteristic of TRAPS from a clinical, genetic e biological point of view. Different treatment option will be reviewed focusing in particular on the available study demonstrating the efficacy of Canakinumab in patients with TRAPS.Expert opinion: TRAPS is a severe disease with a deep impact on patients’ quality of life. There is now strong evidence that IL-1 blockade is the best strategy in those patients and canakinumab the drug of choice.